In this cross-sectional study, manufacturer coupon use for candidate hop biologics diverged from comparators as originators neared exclusivity loss, suggesting coupons may facilitate product hopping. Regulators should consider monitoring coupon programs during biologic exclusivity transitions.
Gibbons et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: